Filing Analysis
Instil Bio, Inc. filed an 8-K to provide a corporate update and announce its financial results for the quarter ended June 30, 2026.
📋 Key Facts
- Report date: August 13, 2026
- Reporting period: Quarter ended June 30, 2026
- The filing includes a press release (Exhibit 99.1) containing financial results and corporate updates.
- Company is an emerging growth company.
Instil Bio, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 11, 2026. Stockholders elected two Class II directors and ratified the appointment of RSM US LLP as the independent registered public accounting firm for the 2026 fiscal year.
📋 Key Facts
- Annual Meeting held on June 11, 2026.
- Quorum achieved with 5,757,919 shares represented (approx. 84.9% of 6,781,976 outstanding shares).
- George Matcham and Neil Gibson were elected as Class II directors until the 2029 Annual Meeting.
- RSM US LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Instil Bio, Inc. reported its financial results for the first quarter ended March 31, 2026, and provided a general corporate update. The information was disclosed via a press release furnished as an exhibit to the filing.
📋 Key Facts
- Financial results cover the quarter ended March 31, 2026.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- The filing includes a press release (Exhibit 99.1) dated May 15, 2026.
- The information is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Instil Bio, Inc. dismissed Deloitte & Touche LLP as its independent registered public accounting firm and appointed RSM US LLP, effective April 1, 2026. The company reported no disagreements or reportable events regarding accounting principles or disclosures during the fiscal years 2024 and 2025.
🚩 Red Flags
- Down-tiering of auditor from a 'Big Four' firm (Deloitte) to a mid-tier firm (RSM), which can sometimes precede changes in financial reporting complexity or cost-cutting measures.
📋 Key Facts
- Dismissed Deloitte & Touche LLP as the independent auditor effective April 1, 2026.
- Appointed RSM US LLP as the new independent auditor for the fiscal year ending December 31, 2026.
- Deloitte's audit reports for the fiscal years ended December 31, 2025 and 2024 contained no adverse opinions or qualifications.
- No disagreements were reported with Deloitte on any matters of accounting principles, practices, or financial statement disclosures.
- The filing includes a letter from Deloitte (Exhibit 16.1) agreeing with the company's statements.
Instil Bio, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2025, and provided a corporate update. The announcement was made via a press release furnished as an exhibit to the 8-K filing.
📋 Key Facts
- Financial results cover the fourth quarter and the full fiscal year ended December 31, 2025.
- The report was filed on March 27, 2026, under Item 2.02 (Results of Operations and Financial Condition).
- The filing includes a press release (Exhibit 99.1) containing the detailed corporate update.
- The information is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Instil Bio's subsidiary, Axion Bio, Inc., has terminated a License and Collaboration Agreement with ImmuneOnco Biopharmaceuticals (Shanghai) Inc. effective January 5, 2026.
🚩 Red Flags
- Termination of a collaboration agreement can signal strategic shifts or difficulties in meeting milestones/commercialization expectations for the specific assets (AXN-2510 and AXN-27M).
📋 Key Facts
- The agreement being terminated was originally dated August 1, 2024.
- The termination involves ex-China development and commercial rights to AXN-2510 and AXN-27M.
- Axion Bio, Inc. is a wholly-owned subsidiary of Instil Bio, Inc.
Instil Bio, Inc. filed an 8-K to provide a corporate update and announce financial results for the quarter ended September 30, 2025.
📋 Key Facts
- Report date: November 13, 2025
- Reporting period: Quarter ended September 30, 2025
- The filing includes a press release (Exhibit 99.1) containing financial results and corporate updates.
- Company is an emerging growth company.
Instil Bio, Inc. filed an 8-K to provide a corporate update and announce its financial results for the quarter ended June 30, 2025.
📋 Key Facts
- Report date: August 13, 2025
- Reporting period: Quarter ended June 30, 2025
- The filing includes a press release (Exhibit 99.1) containing financial results and corporate updates.
- Company is classified as an emerging growth company.
Instil Bio reported preliminary Phase 2 safety and efficacy data from a clinical trial conducted by ImmuneOnco for the combination of '2510 and chemotherapy in NSCLC patients. The results show positive partial response rates and a favorable safety profile with no dose-limiting toxicities.
🚩 Red Flags
- Majority of efficacy evaluable patients had only one tumor assessment at data cut-off (limited long-term durability data).
📋 Key Facts
- Trial: Phase 2 open-label, multicenter study of IMM2510/AXN-2510 ('2510) + chemotherapy for first-line advanced NSCLC.
- Efficacy: 62% partial response rate in efficacy evaluable patients (8/10 squamous; 5/11 non-squamous).
- Safety: No dose-limiting toxicities observed in 33 safety evaluable patients.
- Adverse Events: No treatment-related adverse events (TRAE) leading to death or dose reduction; only one TRAE led to discontinuation.
- Data Cut-off: As of July 1, 2025.
Instil Bio, Inc. held its 2025 Annual Meeting of Stockholders on May 28, 2025. The meeting resulted in the election of a new Class I director and the ratification of Deloitte & Touche LLP as the independent auditor for the fiscal year ending December 31, 2025.
📋 Key Facts
- Annual Meeting held on May 28, 2025.
- Quorum reached with 5,871,933 shares (approx. 89.5% of outstanding common stock) present or represented by proxy.
- Bronson Crouch elected to the Board of Directors as Class I director until the 2028 Annual Meeting.
- Stockholders ratified Deloitte & Touche LLP as independent registered public accounting firm for FY ending Dec 31, 2025.
Instil Bio announced clinical trial updates for its PD-L1xVEGF bispecific antibody, '2510, in collaboration with ImmuneOnco Biopharmaceuticals. The company reported positive safety trends and enrollment progress in China, while pivoting its U.S. clinical strategy toward a monotherapy dose optimization trial.
🚩 Red Flags
- Clinical strategy shift: The U.S. program has moved from a combination therapy approach to a monotherapy dose optimization trial, which may change the value proposition of the asset in the US market.
📋 Key Facts
- Phase 2 trial enrollment for '2510 + chemotherapy in first-line NSCLC (China) is expected to complete in Q3 2025.
- Initial safety and efficacy results from the Phase 2 China trial are anticipated in 2H 2025.
- Preliminary safety data shows a reduction in infusion-related reactions (IRRs): 29.2% for combination therapy vs. 60.4% for monotherapy.
- Phase 1 trial of '2510 monotherapy in relapsed/refractory NSCLC showed an objective response rate (ORR) of 23.1%.
- Company plans to initiate a Phase 1b/2 U.S. trial of '2510 monotherapy before the end of 2025.
- A Phase 3 trial in China is anticipated for mid-2026, pending regulatory discussions.
Instil Bio, Inc. filed an 8-K to provide a copy of its most recent corporate presentation as part of Regulation FD disclosure. The filing does not contain material financial changes or structural shifts.
📋 Key Facts
- The company is distributing a corporate presentation dated May 2025 (Exhibit 99.1).
- The information is furnished under Item 7.01 and is not considered 'filed' for purposes of Section 18 liability.
- Filed on May 22, 2025, by Sandeep Laumas, M.D., CFO/CBO.
Instil Bio, Inc. filed an 8-K to provide a corporate update and announce its financial results for the fiscal quarter ended March 31, 2025.
📋 Key Facts
- Report date: May 13, 2025
- Reporting period: Quarter ended March 31, 2025
- The filing includes a press release (Exhibit 99.1) containing financial results and corporate updates.
- Company is classified as an emerging growth company.
Instil Bio, Inc. entered into an Open Market Sale Agreement (ATM offering) with Jefferies LLC to sell up to $100.0 million of common stock from time to time.
🚩 Red Flags
- Potential for significant shareholder dilution through the issuance of new common stock.
- ATM offerings are often used by micro-cap/biotech companies to bolster cash runways, which can signal immediate liquidity needs.
📋 Key Facts
- Entered into an Open Market Sale Agreement with Jefferies LLC on March 28, 2025.
- The agreement allows for the sale of up to $100.0 million in aggregate offering price of common stock.
- Sales will be conducted via 'at the market' (ATM) methods on Nasdaq or other trading markets.
- Agent compensation is set at 3.0% of the gross sales price per share sold.
- The agreement terminates upon reaching the $100M cap or with 10 days' advance notice.
Instil Bio, Inc. issued a corporate update announcing its financial results for the fourth quarter and full year ended December 31, 2024. The filing includes a press release of earnings and an updated corporate presentation.
📋 Key Facts
- Reported financial results for Q4 and Full Year ended December 31, 2024.
- Issued a new corporate presentation to the investment community on March 4, 2025.
- The company is classified as an 'emerging growth company'.
- Information in Items 2.02 and 7.01 are furnished but not filed for purposes of Section 18 liability.
Instil Bio, Inc. filed an 8-K to announce clinical progress in China regarding its PD-L1xVEGF bispecific antibody, IMM2510/SYN-2510.
📋 Key Facts
- The filing is a press release announcement dated January 14, 2025.
- Focuses on clinical progress for the asset IMM2510/SYN-2510 (also known as SYN-2510).
- The asset is described as a Clinical-Stage PD-L1xVEGF Bispecific Antibody.
Instil Bio's subsidiary, Complex Therapeutics LLC, entered into a $85.6 million term loan agreement with Midland National Life Insurance Company to refinance existing construction debt on a property in Tarzana, California. The new loan features a fixed interest rate of 6.35% and includes specific financial covenants regarding net worth and liquidity.
🚩 Red Flags
- Recourse Indemnity Agreement: While generally non-recourse, the Company is liable for full recourse in events of voluntary bankruptcy, insolvency proceedings, or substantive consolidation.
- Strict Financial Covenants: Requirement to maintain $17.1 million in minimum liquidity and $50 million net worth creates potential pressure on cash management.
📋 Key Facts
- Borrower: Complex Therapeutics LLC (wholly-owned subsidiary of Instil Bio, Inc.)
- Lender: Midland National Life Insurance Company
- Principal Amount: $85.6 million
- Closing Date: December 20, 2024
- Interest Rate: 6.35% per annum (fixed)
- Term: Two years with a one-year extension option
- Repayment: Interest-only payments during the term; principal due at maturity
- Security: First mortgage lien on the Tarzana, CA property and first priority security interest in all other assets of Borrower
- Financial Covenants: Must maintain consolidated net worth $\ge$ $50 million (excl. Property interest) and minimum liquidity $\ge$ $17.1 million
- Prepayment Terms: Prepayment fee applies if prepaid within the first 12 months to make lender whole on interest.
Instil Bio, Inc. filed an 8-K to provide a corporate update and announce its financial results for the quarter ended September 30, 2024.
📋 Key Facts
- Report date: November 13, 2024
- Reporting period: Quarter ended September 30, 2024
- The filing includes a press release (Exhibit 99.1) containing financial results and corporate updates.
- Company is an emerging growth company.
Instil Bio, Inc. issued an 8-K to provide a corporate presentation (Item 7.01) and announce a global registrational strategy for its PD-L1xVEGF bispecific antibody, SYN-2510/IMM2510, targeting Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer (Item 8.01).
📋 Key Facts
- Company released a corporate presentation dated September 2024.
- Announced global registrational strategy for SYN-2510/IMM2510 in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer.
- The filing includes Exhibit 99.1 (Corporate Presentation) and Exhibit 99.2 (Press Release).
Instil Bio, Inc. announced a restructuring plan on September 1, 2024, to close its remaining Manchester, UK operations and eliminate the local workforce by year-end 2024.
🚩 Red Flags
- Significant restructuring costs ($5.5M) relative to typical micro-cap cash positions.
- Asset impairment charges indicate a write-down of value in UK operations.
- Complete exit from an international operational hub (Manchester, UK).
📋 Key Facts
- Restructuring Plan approved by Board of Directors on September 1, 2024.
- Total estimated restructuring costs: up to $5.5 million.
- Includes asset impairment charges of up to $2.2 million.
- Employee termination/severance costs estimated at up to $2.0 million.
- Contract termination costs estimated at up to $1.3 million.
- Workforce reduction expected to be complete by the end of 2024.
Instil Bio, Inc. filed an 8-K to provide a copy of its most recent business presentation (SYN-2510 Program Overview) as part of its ongoing investor relations activities under Regulation FD.
📋 Key Facts
- The filing is primarily for the purpose of distributing a business presentation via Exhibit 99.1.
- The attached exhibit provides an overview of the 'SYN-2510 Program'.
- The information provided in the exhibit is furnished under Item 7.01 and is not considered 'filed' for purposes of Section 18 liability.
Instil Bio, Inc. filed an 8-K to provide a corporate update and announce its financial results for the quarter ended June 30, 2024.
📋 Key Facts
- Report date: August 13, 2024
- Reporting period: Quarter ended June 30, 2024
- The filing includes a press release (Exhibit 99.1) containing financial results and corporate updates.
- Company is an emerging growth company.
Instil Bio's subsidiary, SynBioTx, entered into a major license and collaboration agreement with ImmuneOnco Biopharmaceuticals to develop bispecific antibodies (PD-L1/VEGF) and monoclonal antibodies (CTLA-4) outside of Greater China. The deal includes significant upfront payments and massive potential milestone payments totaling up to $2.1 billion.
🚩 Red Flags
- The agreement includes a clause allowing ImmuneOnco to terminate the entire agreement if Instil Bio/SynBioTx challenges patent validity.
- Significant portion of value is tied to long-term commercial milestones ($1.8B) which are highly speculative in biotech.
📋 Key Facts
- Agreement date: August 1, 2024
- Parties: SynBioTx, Inc. (subsidiary of Instil Bio) and ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- Scope: Exclusive license for PD-L1/VEGF bispecific antibodies (including IMM2510) and CTLA-4 monoclonal antibodies (including IMM27M) outside Greater China.
- Upfront/Near-term payments to ImmuneOnco: Up to $50 million (includes $10 million upfront).
- Potential milestones: Up to $2.1 billion ($270M development/regulatory; $1.8B commercial).
- Royalties: Single-digit to low double-digit percentage on global net sales outside Greater China.
- Termination rights: 180 days' notice for convenience by SynBioTx; termination for material breach or patent challenge.
Instil Bio's wholly owned subsidiary, Complex Therapeutics LLC, entered into a long-term lease agreement with AstraZeneca Pharmaceuticals LP for a facility in Tarzana, CA. The lease provides significant rental income to the company over an initial 15-year term.
🚩 Red Flags
- None identified in this filing
📋 Key Facts
- Lease commencement date: July 10, 2024
- Initial term: Approximately 15 years (ending July 31, 2039)
- Tenant: AstraZeneca Pharmaceuticals LP
- Landlord: Complex Therapeutics LLC (wholly owned subsidiary of Instil Bio, Inc.)
- Base rent: $627,276.00 per month ($7,527,312.00 annually)
- Rent escalation: 3% per annum
- Tenant has two 5-year extension options and a one-time termination option on the 10th anniversary
- Includes rent abatement during the first year of the lease
- Tenant holds a right of first offer to purchase the premises
Instil Bio, Inc. held its 2024 Annual Meeting of Stockholders on June 13, 2024. The meeting resulted in the election of two Class III directors and the ratification of Deloitte & Touche LLP as the company's independent auditor for the fiscal year ending December 31, 2024.
📋 Key Facts
- Annual Meeting held on June 13, 2024.
- Approximately 88.20% of outstanding common stock (5,737,089 shares) was represented at the meeting.
- R. Kent McGaughy, Jr. and Dr. Gwendolyn Binder were elected to the Board of Directors as Class III directors until the 2027 Annual Meeting.
- Stockholders ratified Deloitte & Touche LLP as the independent registered public accounting firm for FY2024.
Instil Bio, Inc. filed an 8-K to provide a corporate update and announce its financial results for the quarter ended March 31, 2024.
📋 Key Facts
- Report date: May 10, 2024
- Reporting period: Quarter ended March 31, 2024
- The filing includes a press release (Exhibit 99.1) containing financial results and corporate updates.
- Company is classified as an emerging growth company.
Instil Bio, Inc. announced the immediate resignation of Jack B. Nielsen from its Board of Directors for personal reasons. The departure is not related to any disagreements with company operations or policies.
🚩 Red Flags
- None identified; the filing explicitly states there was no disagreement with the Company or the Board.
📋 Key Facts
- Jack B. Nielsen resigned from the Board of Directors effective April 24, 2024.
- The resignation was for personal reasons and not due to any disagreement regarding company operations, policies, or practices.
- George Matcham, Ph.D., a current Board member, has been appointed to serve on the Audit Committee.
Instil Bio, Inc. filed an 8-K to provide a corporate update and announce its financial results for the fourth quarter and full year ended December 31, 2023.
📋 Key Facts
- Report date: March 21, 2024
- Reporting period: Fourth quarter and full year ended December 31, 2023
- The filing includes a press release (Exhibit 99.1) containing financial results and corporate updates.
- Company is classified as an emerging growth company.
Instil Bio, Inc. entered into one-year retention bonus agreements for its CEO and CFO/CBO to ensure leadership stability through February 12, 2025.
🚩 Red Flags
- Retention bonuses can sometimes signal underlying concerns regarding executive turnover risk in micro-cap biotech firms.
📋 Key Facts
- CEO Bronson Crouch granted a $462,825 retention bonus if employed in good standing through Feb 12, 2025.
- CFO/CBO Sandeep Laumas, M.D. granted a $254,300 retention bonus if employed in good standing through Feb 12, 2025.
- Bonuses are subject to pro-rated repayment if terminated for Cause or resigned without Good Reason before the retention date.
- The agreements include protections for termination without Cause or resignation for Good Reason.
Instil Bio, Inc. provided an update regarding a collaboration for preclinical manufacturing feasibility studies within its ITIL-306 program. The company aims to enroll patients in investigator-initiated (IIT) clinical trials but provides no specific timeline for data readouts.
🚩 Red Flags
- Lack of visibility into data readout timelines, which is common in early-stage biotech but increases uncertainty for investors.
📋 Key Facts
- The company is conducting preclinical manufacturing feasibility studies as part of the ITIL-306 program.
- The goal of these studies is to enable patient enrollment in investigator-initiated (IIT) clinical trials.
- Management explicitly stated they are providing no guidance regarding the timing of data readouts for the ITIL-306 program or IIT studies.
Instil Bio is executing a significant restructuring plan involving the closure of its Manchester, UK manufacturing and clinical trial operations. This move includes a 61% reduction in the UK workforce and the cancellation of expected clinical data from the ITIL-306-202 trial for 2024.
🚩 Red Flags
- Significant reduction in operational footprint (closure of UK manufacturing/clinical site).
- Loss of expected clinical data milestones for the year 2024.
- Substantial workforce reduction (61% of UK staff) indicating a pivot or contraction in strategy.
- Potential cash burn implications from $6.1 million in restructuring charges.
📋 Key Facts
- Closure of Manchester, UK manufacturing and clinical trial operations approved on January 14, 2024.
- Workforce reduction of approximately 61% in the UK, expected to be completed by H1 2024.
- Estimated restructuring costs of up to $6.1 million (severance, benefits, and contract terminations).
- The Company will no longer report clinical data from the ITIL-306-202 clinical trial in 2024.